Celestina Barbosa-Leiker1,2,3, Sterling McPherson2,3,4, Matthew E Layton2,3,4, Ekaterina Burduli2,3,4, John M Roll2,3,4, Walter Ling5,6. 1. a College of Nursing , Washington State University , Spokane , WA , USA. 2. b Program of Excellence in Addictions Research , Washington State University , Spokane , WA , USA. 3. c Translational Addictions Research Center , Washington State University , Spokane , WA , USA. 4. d Elson S. Floyd College of Medicine , Washington State University , Spokane , WA , USA. 5. e Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine , University of California , Los Angeles , CA , USA. 6. f Integrated Substance Abuse Programs , University of California , Los Angeles , CA , USA.
Abstract
BACKGROUND: There are sex differences in buprenorphine/naloxone clinical trials for opioid use. While women have fewer opioid-positive urine samples, relative to men, a significant decrease in opioid-positive samples was found during treatment for men, but not women. In order to inform sex-based approaches to improve treatment outcomes, research is needed to determine if opioid use, and predictors of opioid use, differs between men and women during treatment. OBJECTIVES: To test for sex differences in opioid use during a buprenorphine/naloxone clinical trial and determine if sex differences exist in the associations between addiction-related problem areas and opioid use over the course of the trial. METHOD: This secondary data analysis of the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003 examined sex differences (men = 347, women = 169) in opioid-positive samples in a randomized clinical trial comparing 7-day vs. 28-day buprenorphine/naloxone tapering strategies. Addiction-related problem areas were defined by Addiction Severity-Lite (ASI-L) domain composite scores. RESULTS: Women were more likely than men to use opioids during the course of the buprenorphine/naloxone clinical trial (B = .33, p = .01) and medical issues were positively related to submitting an opioid-positive sample during treatment for women (B = 1.67, p = .01). No ASI-L domain composite score was associated with opioid-positive samples during treatment for men. CONCLUSION: Women were more likely than men to use opioids during the course of the buprenorphine/naloxone clinical trial, and medical issues predicted opioid use during treatment for women but not men. Complementary treatment for medical problems during opioid replacement therapy may benefit women.
RCT Entities:
BACKGROUND: There are sex differences in buprenorphine/naloxone clinical trials for opioid use. While women have fewer opioid-positive urine samples, relative to men, a significant decrease in opioid-positive samples was found during treatment for men, but not women. In order to inform sex-based approaches to improve treatment outcomes, research is needed to determine if opioid use, and predictors of opioid use, differs between men and women during treatment. OBJECTIVES: To test for sex differences in opioid use during a buprenorphine/naloxone clinical trial and determine if sex differences exist in the associations between addiction-related problem areas and opioid use over the course of the trial. METHOD: This secondary data analysis of the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003 examined sex differences (men = 347, women = 169) in opioid-positive samples in a randomized clinical trial comparing 7-day vs. 28-day buprenorphine/naloxone tapering strategies. Addiction-related problem areas were defined by Addiction Severity-Lite (ASI-L) domain composite scores. RESULTS:Women were more likely than men to use opioids during the course of the buprenorphine/naloxone clinical trial (B = .33, p = .01) and medical issues were positively related to submitting an opioid-positive sample during treatment for women (B = 1.67, p = .01). No ASI-L domain composite score was associated with opioid-positive samples during treatment for men. CONCLUSION:Women were more likely than men to use opioids during the course of the buprenorphine/naloxone clinical trial, and medical issues predicted opioid use during treatment for women but not men. Complementary treatment for medical problems during opioid replacement therapy may benefit women.
Entities:
Keywords:
Opioid dependence; addiction severity index; buprenorphine/naloxone; sex differences
Authors: John S Cacciola; Arthur I Alterman; A Thomas McLellan; Yi-Ting Lin; Kevin G Lynch Journal: Drug Alcohol Depend Date: 2006-10-11 Impact factor: 4.492
Authors: Rebekah D Tenney; Steven Blake; Paul T Bremer; Bin Zhou; Candy S Hwang; Justin L Poklis; Kim D Janda; Matthew L Banks Journal: Neuropharmacology Date: 2019-07-29 Impact factor: 5.250
Authors: Kathryn L Schwienteck; Steven Blake; Paul T Bremer; Justin L Poklis; E Andrew Townsend; S Stevens Negus; Matthew L Banks Journal: Drug Alcohol Depend Date: 2019-08-24 Impact factor: 4.492